Alex Dahmani

Company: Adaptive Biotech

Job title: Director, Business Development

Seminars:

Monitoring Infused Treg Cells in vivo to Predict Response, Remission and Relapse 10:00 am

Cell therapy outcomes in oncology have shown that a durable response is associated with persistence of the infusion product in vivo Adaptive’s highly-sensitive immune sequencing technology characterizes the full TCR repertoire of the infusion product The endogenous TCR can be used to track infused Treg clones in vivo in order to measure persistence and predict…Read more

day: Day Two